@article {Leone2022.11.14.22282124, author = {MA Leone and M Gelati and DC Profico and C Conti and C Spera and G Muzi and V Grespi and I Bicchi and C Ricciolini and D Ferrari and M Zarrelli and L Amoruso and G Placentino and P Crociani and F Apollo and P Di Viesti and D Fogli and T Popolizio and C Colosimo and D Frondizi and G Stipa and E Tinella and A Ciampini and S Sabatini and F Paci and G Silveri and C Gobbi and E Pravat{\`a} and E Zecca and RF Balzano and J Kuhle and M Copetti and A Fontana and M Carella and G D{\textquoteright}Aloisio and L Abate and S Pluchino and L Peruzzotti-Jametti and AL Vescovi}, title = {Foetal Allogeneic Intracerebroventricular Neural Stem Cell Transplantation in People with Secondary Progressive Multiple Sclerosis: A phase I dose-escalation clinical trial}, elocation-id = {2022.11.14.22282124}, year = {2022}, doi = {10.1101/2022.11.14.22282124}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Advanced cell therapeutics are emerging as potentially effective treatments for chronic neurological diseases, including secondary progressive multiple sclerosis (SPMS). Here we report the results of a phase I trial in which good manufacturing practice-grade foetal allogeneic human neural stem cells (hNSCs) were implanted via intracerebroventricular (ICV) injection in 15 individuals with active and non-active SPMS.Methods This is a phase I, open-label, multicentre, dose-escalation, international study. The primary objective was to assess the feasibility, safety, and tolerability of ICV injections of allogeneic hNSCs in patients affected by SPMS over a study follow up of 12 months. We also evaluated the number and type of adverse events (AEs) leading to a maximum tolerated dose, the general health status, and mortality. The secondary objectives were the therapeutic benefit of allogeneic hNSCs using assessment scales, magnetic resonance imaging (MRI), and laboratory and neurophysiologic parameters.Findings Fifteen unrelated SPMS patients were enrolled and treated between 2018 and 2020. The participants had a median age of 49.8 years. Their mean extended disability status scale (EDSS) at enrolment was 7.6, the mean disease duration was 22 years, and mean time from diagnosis to progression was 10.1 years. Neither treatment-related deaths nor serious AEs were reported during the study (1 year follow up after treatment). All the other AEs were classified as non-serious and were associated to non-study concomitant therapy or other medical conditions not connected to the experimental treatment. During the study, none of the participants worsened in the progression of their SPMS as shown by the evaluation scales implemented to assess their progress. Laboratory and neurophysiologic parameters showed no clinically significant variations. MRI follow-up showed non-clinically significant type 1, 2, and 3 changes.Interpretation The intracerebroventricular injection of foetal allogeneic hNSCs in people with SPMS is feasible, tolerated and safe. Study participants displayed a substantial clinical stability during the 12-month follow-up. The absence of relevant adverse reactions (Ars) arising from the transplantation of hNSCs indicates a short-term neutral balance between benefits and risks and suggests a concrete, though perspective therapeutic possibility for SPMS patients. Further studies are needed to confirm and extend the findings herein and evaluate the actual therapeutic potential of advanced cell therapeutics for a condition where the lack of effective disease modifying therapies is a major unmet clinical need.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03282760Funding StatementSupport for writing, proofreading and submission assistance was funded by IRCCS Casa Sollievo della Sofferenza Research Hospital, Italy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of IRCCS Casa Sollievo della Sofferenza gave ethical approval for this work Ethics committee of Azienda Ospedaliera S. Maria di Terni ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2022/11/15/2022.11.14.22282124}, eprint = {https://www.medrxiv.org/content/early/2022/11/15/2022.11.14.22282124.full.pdf}, journal = {medRxiv} }